News & Articles

Watch this on-demand webinar to learn how COVID immune responses can be assessed using a novel microfluidic in-solution immunoassay platform

Dr. Chris Mason shares his extensive research into the SARS-CoV-2 immune response and the similarities experienced by astronauts landing back on Earth

Researchers recommend that targeted nutrition should be urgently explored as a counter-measure to mitochondrial damage

Designed to enrich pathologists' skills in biomarker interpretation and scoring techniques

The assay is developed for use in detection, characterisation, and monitoring of the SARS-CoV-2 virus

Watch this on-demand webinar with Dr. Petter Brodin to learn about new insights into the immune response to SARS-CoV-2

Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

Susie Harborth explores what it takes to be a scientist entrepreneur and highlights the technology driving innovation in bioscience

Two different dosing regimens demonstrated efficacy with one showing a better profile

The collaboration aims to secure manufacturing and testing capacity in the next phase of the pandemic

Observations of rapid recovery on chest x-rays noted and no drug-related Serious Adverse Events reported

The new lots further enhance Lonza’s renowned human primary cell offerings as it looks to meet growing market demand for deeper cell characterization

Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing

QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes

Non-invasive sample collection and batch processing to test symptomatic and asymptomatic individuals

Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide

The kit promises to be a low cost, high-sensitivity diagnostic test for COVID-19 detection

The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR